Harmony Biosciences Holdings (HRMY) Gross Profit (2020 - 2026)

Harmony Biosciences Holdings (HRMY) has 7 years of Gross Profit data on file, last reported at $170.9 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 11.87% year-over-year to $170.9 million; the trailing twelve-month figure through Mar 2026 stood at $688.2 million (up 17.95% YoY), and the FY2025 full-year result was $670.1 million, up 20.11% from the prior year.
• Gross Profit retreated to $170.9 million in Q1 2026, from $175.2 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $179.8 million in Q3 2025 to a low of $70.6 million in Q1 2022.
• A 5-year average of $130.2 million and a median of $128.0 million in 2023 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit surged 44.12% in 2022 and grew 11.87% in 2026, its largest moves.
• Tracing HRMY's Gross Profit over 5 years: stood at $101.4 million in 2022, then advanced by 23.5% to $125.3 million in 2023, then rose by 17.24% to $146.9 million in 2024, then climbed by 19.32% to $175.2 million in 2025, then retreated by 2.49% to $170.9 million in 2026.
• Business Quant data shows HRMY's Gross Profit at $170.9 million in Q1 2026, $175.2 million in Q4 2025, and $179.8 million in Q3 2025.